Article,
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
Contributors
Winter, David L.
0000-0002-1597-4081
[1]
Teepen, Jop
0000-0002-2647-2677
[2]
ALLODJI, RODRIGUE
0000-0002-1895-8415
[3]
[4]
[5]
[6]
Belle, Fabien N.
0000-0002-0037-4817
[7]
[8]
Bagnasco, Francesca
0000-0003-1601-9518
[9]
[10]
Bardi, Edit
0000-0001-7424-6255
[12]
[13]
[14]
Ronckers, Cecile
0000-0003-3524-4657
[2]
[15]
Haddy, Nadia
0000-0001-9316-8280
[3]
[4]
[5]
[6]
Gudmundsdottir, Thorgerdur
0000-0001-6396-1018
[16]
[17]
Van der Pal, Helena
0000-0003-2253-2115
[2]
Schindera, Christina
0000-0002-4511-287X
[8]
[22]
Kaiser, Melanie
0000-0002-3362-2530
[23]
Michel, Gisela
0000-0002-9589-0928
[27]
Skinner, Roderick
0000-0002-1162-675X
[28]
[29]
Dugue, P. -A.
0000-0003-2736-3023
[24]
[25]
[26]
Terenziani, Monica
0000-0002-7080-6718
[33]
Winther, Jeanette
0000-0002-3440-5108
[17]
[34]
Lahteenmaki, Paeivi M.
0000-0002-5500-9606
[35]
Zadravec Zaletel, Lorna
0000-0002-4423-0276
[36]
Kuehni, Claudia
0000-0001-8957-2002
[8]
[37]
Kremer, Leontien
0000-0001-7422-3248
[2]
[38]
de Vathaire, Florent
0000-0002-8374-9281
[3]
[4]
[5]
[6]
Hjorth, Lars
0000-0002-8302-7174
[18]
[19]
Reulen, Raoul
0000-0002-7328-0467
(Corresponding author)
[1]
Affiliations
- [1] Univ Birmingham, Ctr Childhood Canc Survivor Studies, Inst Appl Hlth Res, Birmingham, W Midlands, England [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [2] Princess MAxima Ctr Pediat Oncol, Utrecht, Netherlands [NORA names: Netherlands; Europe, EU; OECD];
- [3] Gustave Roussy, Dept Children & Adolescents Oncol, F-94805 Villejuif, France [NORA names: France; Europe, EU; OECD];
- [4] Univ Paris Saclay, Ctr Res Epidemiol & Populat Hlth, INSERM U1018, Radiat Epidemiol Team,Gustave Roussy, Villejuif, France [NORA names: France; Europe, EU; OECD];
- [5] Gustave Roussy, Dept Children & Adolescents Oncol, F-94805 Villejuif, France [NORA names: France; Europe, EU; OECD];
(... more)
Abstract
Background Survivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks. Methods The PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. Results One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4-5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6-25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7-11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9-9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0-8.5). Survivors treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3-44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6-100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1-70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6-23.7). Conclusions Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early.
